Guidelines. For patients with atrial fibrillation aged 75 or younger who are at high risk of stroke (see table) and are deemed safe candidates for anticoagulation, treatment with warfarin and a target INR of 2.5 (range 2.0 to 3.0) is recommended.
Options. For those over age 75 years, a lower INR target of 2.0 (range 1.6 to 2.5) may be acceptable to minimize risk of bleeding. However, because this lower intensity anticoagulation has not been separately established as adequately efficacious for high-risk patients with AF, a higher target INR of 2.5 (range 2.0 to 3.0) is recommended for such patients regardless of age as an alternative.
For patients with AF deemed unable to receive anticoagulants or those deemed to be at low risk of stroke (see table) , aspirin (325 mg/day) is recommended. However, aspirin has not been established as efficacious for these specific subgroups of patients with atrial fibrillation by clinical trials.
For patients with AF considered to have a moderate risk of stroke, the choice of warfarin or aspirin should particularly consider the individual patient's bleeding risk during anticoagulation and patient preferences. Stroke risk with aspirin ≈8%/y ‡ ≈3.5%/y ≈1%/y * In the AFI/ACCP Consensus conference scheme, the ischemic stroke rate in those without high-risk features was 1.6%/y in the age group 60-69 y, 2.1% in those 70-79 y, and 3.0%/y in those over age 80 y. 7 † Impaired left ventricular function included recent congestive heart failure or fractional shortening ≤25% by M-mode echocardiography. ‡ For those without prior stroke/TIA, the estimated event rate was ≈6%/y; for those with prior stroke/TIA it was nearly 12%/y; those with multiple risk factors have even higher stroke rates. Future research. A key issue is the reliable stratification of stroke risk to identify AF patients at high versus low risk of ischemic stroke. The generalizability of current risk stratification schemes based on clinical trials (see table) to clinical practice warrants further study. The optimal intensity of anticoagulation for subgroups of AF patients (e.g., very elderly or those with prior stroke) and better quantitative definition of contraindications to anticoagulation merit further investigation to permit safer, more efficacious anticoagulation.
SPAF = Stroke Prevention in Atrial Fibrillation
The effects of cardioversion and pharmacologic efforts to maintain sinus rhythm on stroke risk and quality of life remain to be determined.
Patient preference for use of aspirin versus warfarin (and required monitoring as well as increased cost of the latter) must be taken into account in selecting appropriate therapy for stroke prevention.
